Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children.
Kristensen M. et al, (2024), Cell reports. Medicine, 5
Respiratory Syncytial Virus-related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study.
Wiseman DJ. et al, (2024), American journal of respiratory and critical care medicine, 210, 994 - 1001
Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal influenza vaccines (ComFluCOV).
Lazarus R. et al, (2024), Vaccine, 42
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Maytum A. et al, (2024), The Pediatric infectious disease journal, 43, 809 - 812
An open-label, phase IV randomised controlled trial of two schedules of a four-component meningococcal B vaccine in UK preterm infants.
Calvert A. et al, (2024), Archives of disease in childhood
Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemic.
Zeller I. et al, (2024), Infection
Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus
Lin G-L. et al, (2024), Nature Communications, 15
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Ratcliffe H. et al, (2023), iScience, 26, 108500 - 108500
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial
Kelly E. et al, (2023), Journal of Infection, 87, 230 - 241
Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children.
Kazmin D. et al, (2023), NPJ vaccines, 8
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X. et al, (2023), The Journal of infection, 87, 18 - 26
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH. et al, (2023), The Journal of infection, 86, 574 - 583
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X. et al, (2023), The Journal of infection, 86, 540 - 541
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287
Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C
Tiley KS. et al, (2023), The Journal of Infectious Diseases, 227, 610 - 621
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Rajan M. et al, (2023), The Pediatric infectious disease journal, 42, 66 - 73
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Mentzer AJ. et al, (2023), Nature Medicine, 29, 147 - 157